Dedicated To Treating
Life-Threatening
Inflammatory Diseases
Affecting the Pancreas,
Kidney and Lung.

Latest News
February 13, 2024
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
More
February 7, 2024
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More
January 22, 2024
CalciMedica Announces Private Placement of up to Approximately $55 Million
More
About Calcimedica

The goal of CalciMedica’s development programs is to explore the therapeutic benefits of CRAC (calcium release-activated calcium) channel inhibitors in inflammatory diseases of the pancreas, kidney, lung and other organs.

Learn More

Leading the Way in CRAC Channel Inhibition: We are developing a new class of therapies that target the inhibition of CRAC channels and are designed to modulate the immune response and protect against tissue cell injury.

Learn About CRAC Channels
THE HIGH UNMET NEEDS WE SEEK to ADDRESS
THE HIGH UNMET NEEDS WE SEEK to ADDRESS-mobile
The High Unmet Needs We Seek To Address

We Develop Therapies
for Life-threatening
Inflammatory Illnesses.

CalciMedica is developing therapeutics that treat serious
illnesses driven by inflammatory processes and direct
cellular damage. Our CRAC channel inhibitors have the
potential to provide therapeutic benefits in life-threatening
inflammatory diseases for which there are currently no
approved disease-modifying treatments.

Targeted Indications
Acute Pancreatitis With Accompanying Systemic Inflammatory Response Syndrome (SIRS)
300
K

Hospitalizations per year in the US, with one third having or developing SIRS, indicative of predicted or severe disease 

  • Standard of care: Supportive care – IV fluids, pain medication, and nutrition
  • Severe complications include pancreatic necrosis, life-threatening distal organ failure, and acute respiratory distress syndrome (ARDS)
  • 20-30% mortality rate in patients with severe disease
Learn More
Asparaginase-Induced Pancreatic Toxicity (AIPT) / Asparaginase-Associated Pancreatitis (AAP)
3,000

Children with acute lymphoblastic leukemia (ALL) treated with chemotherapeutic asparaginase in US annually, 7-10% of whom develop AIPT

  • Standard of care: Supportive care – IV fluids, pain medication, and nutrition
  • >50% of pediatric AIPT patients develop pancreatic necrosis and/or pancreatic pseudocysts 
  • AIPT requires that asparaginase treatment be halted beyond this there can be other short- or long-term consequences
Learn More
Stage 2 or 3 (moderate or severe) Acute Kidney Injury (AKI)
1.1
MM

30% of 3.7MM patients hospitalized annually in the US with AKI are Stage 2 and Stage 3

  • Standard of Care: Supportive care Treatment of complications; dialysis
  • Disease can progress to:
    • Chronic kidney disease
    • End stage renal disease
    • Eventual Death
Learn More
Acute Respiratory Distress Syndrome (ARDS)
200
K

Patients per year in the U.S.
3M Patients per year globally

  • Standard of care: Oxygen and fluid management; invasive mechanical ventilation
  • 10% of intensive care unit admissions worldwide each year. 75-80% moderate or severe. Life-threatening complications including organ damage or organ failure
  • 30-40% mortality rate. Leads to 75,000 deaths annually in the U.S
Learn More
A Leadership Team Dedicated to Science and Innovation.
Our Pipeline

Auxora™

Auxora™, a proprietary, intravenous formulation of a small
molecule calcium release-activated calcium (CRAC) channel
inhibitor, is in development for the treatment of acute
pancreatitis (AP) with SIRS and asparaginase-induced pancreatic
toxicity (AIPT), for which there are no currently approved
therapies.

Who_we_are
Who_we_are
Who We Are

A Leadership Team
Dedicated to Science and
Innovation.

The CalciMedica team is comprised of scientists, physicians,
drug development experts and entrepreneurs dedicated to
the development of CRAC channel inhibitors for acute and
chronic inflammatory conditions.

Who_we_are
Who_we_are
About CalciMedica

“Our focus at CalciMedica is on developing and bringing to market an entirely new class of therapies – CRAC channel inhibitors – to fight life-threatening inflammatory diseases of the pancreas, kidney, and lung. We are dedicated to addressing the high unmet need for safe and effective therapies to benefit patients with acute illnesses for which there are currently no approved treatments.”

A. RACHEL LEHENY, PH.D.,
Chief Executive Officer
Latest News
February 13, 2024
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
More
February 7, 2024
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More
January 22, 2024
CalciMedica Announces Private Placement of up to Approximately $55 Million
More